Monopar presents Phase 2 data showing ALXN1840 rapidly improves copper balance in Wilson disease

Monopar Therapeutics

Oral presentation at AASLD 2025: 'Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline.'
Mean daily copper balance significantly improved vs. pre-treatment baseline in 8 patients on ALXN1840.
Improvement observed during 15 mg once-daily (days 1-28) and entire treatment period (days 1-39).
Copper balance improved primarily via increased fecal copper excretion; data available on Monopar's website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.